Atrophy of the Substantia innominata on Magnetic Resonance Imaging Predicts Response to Donepezil Treatment in Alzheimer’s Disease Patients
The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
To investigate whether atrophy of the substantia innominata as shown on magnetic resonance imaging (MRI), reflecting degeneration of cholinergic neurons in the nucleus basalis of Meynert, predicts response to donepezil treatment in patients with Alzheimer’s disease (AD), we studied correlations between the thickness of the substantia innominata and clinical efficacy. Eighty-two patients were divided into responders, including transiently and continuously responding groups, and nonresponders, based on the changes in the Mini-Mental State Examination (MMSE) score from baseline at 3 months and at 12 months. Atrophy of the substantia innominata was more pronounced in transiently and continuously responding groups than nonresponders, but no significant change in the thickness between transiently and continuously responding groups was found. The MMSE score changes from baseline at 3 months and at 12 months significantly inversely correlated with the thickness of the substantia innominata. Logistic regression analysis revealed that the overall discrimination rate with the thickness of the substantia innominata was 70% between responders and nonresponders. We conclude that atrophy of the substantia innominata on MRI helps to predict response to donepezil treatment in patients with AD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
SELECTIVE LOSS OF CENTRAL CHOLINERGIC NEURONS IN ALZHEIMER'S DISEASE
DAVIES, P. (1976) · The Lancet · doi:10.1016/s0140-6736(76)91936-x · Cited by 3,565
McKeith, I., Del Ser, T., Spano, P., Emre, M., Wesnes, K., Anand, R., Cicin-Sain, A., Ferrara, R., & Spiegel, R. (2000) · The Lancet · doi:10.1016/s0140-6736(00)03399-7 · Cited by 1,182
Sahakian, B. J., Owen, A. M., Morant, N. J., Eagger, S. A., Boddington, S., Crayton, L., Crockford, H. A., Crooks, M., Hill, K., & Levy, R. (1993) · Psychopharmacology · doi:10.1007/bf02244644 · Cited by 226
Cited by
Clinical neurophysiology of aging brain: From normal aging to neurodegeneration
Rossini, P. M., Rossi, S., Babiloni, C., & Polich, J. (2007) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2007.07.010 · Cited by 525
Sources of cortical rhythms in adults during physiological aging: A multicentric EEG study
Babiloni, C., Binetti, G., Cassarino, A., Dal Forno, G., Del Percio, C., Ferreri, F., Ferri, R., Frisoni, G., Galderisi, S., Hirata, K., et al. (2006) · Human Brain Mapping · doi:10.1002/hbm.20175 · Cited by 314
Babiloni, C., Binetti, G., Cassetta, E., Forno, G. D., Percio, C. D., Ferreri, F., Ferri, R., Frisoni, G., Hirata, K., Lanuzza, B., et al. (2006) · Clinical Neurophysiology · doi:10.1016/j.clinph.2005.09.019 · Cited by 285
Wilcock, G. K., Gauthier, S., Frisoni, G. B., Jia, J., Hardlund, J. H., Moebius, H. J., Bentham, P., Kook, K. A., Schelter, B. O., Wischik, D. J., et al. (2017) · Journal of Alzheimer's Disease · doi:10.3233/jad-170560 · Cited by 219
“The inverse relationship we report is the opposite of that reported for the response to donepezil [31], which varies in proportion with basal forebrain atrophy, and donepezil has also been shown recently to reduce the rate of progression of basal forebrain atrophy in prodromal AD [32].”
ResultBABILONI, C., FRISONI, G., PIEVANI, M., VECCHIO, F., LIZIO, R., BUTTIGLIONE, M., GEROLDI, C., FRACASSI, C., EUSEBI, F., & FERRI, R. (2009) · NeuroImage · doi:10.1016/j.neuroimage.2008.08.005 · Cited by 171
“, 2005), especially in nonresponders to cholinergic therapy (Tanaka et al., 2003).”
Background
Metadata
- Authors
- Tanaka, Y., Hanyu, H., Sakurai, H., Takasaki, M., & Abe, K.
- Venue
- Dementia and Geriatric Cognitive Disorders
- Publisher
- S. Karger AG
- Published
- 2003
- Volume
- 16
- Issue
- 3
- Pages
- 119-125
- ISSN
- 1420-8008 (ISSN-L)
- 1421-9824
- OpenAlex
- W1965749926
- Cited by
- 64
- References
- 3
- FWCI
- 2.73
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.